Market Access

3.24.2014 Market Access

Patient-Reported Outcomes Spurred by Big Data in Pharma

By Nicole May, Research Analyst The opportunities are countless for Big Data in pharma, particularly within the clinical trial space.  Harnessing the data generated during clinical trials could help shorten trial timelines and lead to less expensive...
 

2.26.2014 Account Strategy for Payer Organizations

Provide a Framework for New Product Planning Groups to Influence Clinical Trials

By Jacob Presson, Research Analyst A common theme running through a lot of what we at Cutting Edge Information learn while conducting research on the pharmaceutical industry is the need for more consistent and productive communication between internal...
 

12.23.2013 Market Access

The Price Is (Maybe Not) Right: Watching Your Best Price

By Jacob Presson, Research Analyst Most people who currently work in sales or have done so in the past know the thrill of closing a big deal.  After weeks of working with a client, both sides agree on a price and the papers are signed.  The thrill...
 

11.14.2013 Managed Care Liaison / HOL

A Method to the Madness: Managed Markets Account Managers

By Jacob Presson, Research Analyst As payers demand ever-increasing evidence of product efficacy and cost effectiveness from the pharmaceutical industry, managing relationships with them is growing in strategic importance.  As a result, account...
 

11.7.2013 Health Economics and Outcomes Research (HEOR)

HEORs and Tails: Why Is Staffing Market Access Teams So Difficult?

By Christie Shilling, Research Analyst Pharmaceutical market access teams hold a wide range of responsibilities and, as such, require employees with a variety of knowledge and skills.  Organizations that create a well-rounded market access team...
 

10.31.2013 Health Economics and Outcomes Research (HEOR)

Challenges of Big Data Loom Large Over Pharma

By Nicole May, Research Analyst Big Data strategies face big obstacles as well as big rewards. Research analysts recently discussed problems plaguing Big Data- and analytics-driven teams with pharmaceutical and medical device executives. Similar...
 

9.10.2013 Market Access

Product Pricing in Emerging Markets

By Yanis Saradjian, Director of Consulting In today’s global market, life science companies worldwide face challenges such as increased austerity measures, unfamiliar emerging markets payers and governments, greater emphasis on health economics...
 

9.5.2013 Market Access

Market Access Budgets Rebound After 2012 Patent Cliff

By Natalie DeMasi, Research Analyst In 2012, many key drugs in the US fell off the patent cliff and lost their market exclusivity.  As US pharmaceutical companies watched these products meet their fates, they tried their best to mitigate the damage. ...
 

9.4.2013 Managed Care Liaison / HOL

Ideal Criteria for Finding Top-Notch Health Outcomes Liaisons

By Nicole May, Research Analyst With the expanding emphasis on building payer relationships and demonstrating product value, health outcomes liaison and managed care liaison teams are more important than ever.  The first step to building a strong...
 

8.13.2013 Managed Care Liaison / HOL

Want Top Formulary Postions? You’ll Need a Well-Armed Payer Liaison Team

By Nicole May, Research Analyst Payer meetings are crucial to drug success.  Payer liaison teams, whether they consist of health outcomes liaisons (HOL), managed care liaisons (MCL), or any other medical/economic expert team, must convince payers...